| 產(chǎn)品編號(hào) | bs-4542R |
| 英文名稱(chēng) | BRLF1 Rabbit pAb |
| 中文名稱(chēng) | 立即早期癌基因BRLF1/鼻咽癌基因抗體 |
| 別 名 | RTA_EBVG; barr virus; Replication and transcription activator; Rta; Immediate-early protein Rta; HHV4tp2_gp33; BRLF1 [Human herpesvirus 4 type 2]; HHV-4; |
 |
Specific References (3) | bs-4542R has been referenced in 3 publications.
[IF=11.205] Ruo-Wen Xiao. et al. Rare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication. EBIOMEDICINE. 2022 Oct;84:104267 WB ; Human.
[IF=3.329] Hui D et al. CD44+CD24-/low sphere-forming cells of EBV-associated gastric carcinomas show immunosuppressive effects and induce Tregs partially through production of PGE2. Exp Cell Res. 2020 May 15;390(2):111968. WB ; human.
[IF=0] Granato M et al. Quercetin Interrupts the Positive Feedback Loop Between STAT3 and IL-6, Promotes Autophagy, and Reduces ROS, Preventing EBV-Driven B Cell Immortalization. Biomolecules.?2019 Sep 12;9(9). pii: E482. WB ; Human.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 細(xì)菌及病毒 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | (predicted: HHV-4) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 66.5 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from HHV4tp2 BRLF1: 81-180/605 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Expression of the Epstein-Barr virus (EBV) immediate-early (IE) protein BRLF1 induces the lytic form of viral replication in most EBV-positive cell lines. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some EBV lytic gene promoters. However, BRLF1 activates transcription of the other IE protein, BZLF1, through an indirect mechanism which we previously showed to require activation of the stress mitogen-activated protein kinases. Here we demonstrate that BRLF1 activates phosphatidylinositol-3 (PI3) kinase signaling in host cells. We show that the specific PI3 kinase inhibitor, LY294002, completely abrogates the ability of a BRLF1 adenovirus vector to induce the lytic form of EBV infection, while not affecting lytic infection induced by a BZLF1 adenovirus vector. Furthermore, we demonstrate that the requirement for PI3 kinase activation in BRLF1-induced transcriptional activation is promoter dependent. BRLF1 activation of the SM early promoter (which occurs through a direct binding mechanism) does not require PI3 kinase activation, whereas activation of the IE BZLF1 and early BMRF1 promoters requires PI3 kinase activation. Thus, there are clearly two separate mechanisms by which BRLF1 induces transcriptional activation. BRLF1是EBV的立即早期基因。作為一種反式激活因子，它可以調(diào)節(jié)EBV早期／晚期基因的表達(dá)．并且還可能參與裂解期病毒基因組的復(fù)制。它的表達(dá)與EBV潛伏周期向裂解周期的轉(zhuǎn)換密切相關(guān)。BRLF1的蛋因白產(chǎn)物Rta包含CTL識(shí)別的表位，可能在病毒裂解周期的早期成為免疫系統(tǒng)的作用位點(diǎn)。對(duì)它研究還可能為某些EBV相關(guān)腫瘤的篩查和治療提供線索。 |
